Astrazeneca plc
NASDAQ: AZN
$66.40
+$0.77 (+1.2%)
Closing Price on November 25, 2024
AZN Articles
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.
Published:
Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United States.
Published:
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
Published:
Drug giants Merck and Pfizer reported better-than-expected second-quarter 2014 results before markets opened Tuesday morning.
Published:
Last Updated:
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations seen after the three-day Memorial Day weekend. They include AMC, Cisco, NextEra, NRG and Staples.
Published:
ThinkstockBig news from two of the market’s biggest names is making waves across Wall Street today as stocks advance through a quiet start to the week. The Dow Jones Industrial...
Published:
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
Published:
Last Updated:
Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower in the premarket.
Published:
Last Updated:
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick Gold, Netflix, Teva Pharmaceutical and Valero Energy.
Published:
ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca PLC (NYSE: AZN) is...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 3, 2014. They include Apple, MarkWest Energy Partners, NII Holdings, RF Micro...
Published:
ThinkstockHorizon Pharma Inc. (NASDAQ: HZNP) is having a stellar day after breaking news that it entered into a pact with AstraZeneca PLC (NYSE: AZN) for the U.S. rights to VIMOVO. The move aims to...
Published: